LDL receptor (LDLR) is a cell surface glycoprotein that scavenges LDL from the blood and regulates plasma LDL levels.1 It is composed of an N-terminal signal sequence, a ligand-binding domain, an EGF precursor homology domain, an O-linked glycosylation domain, a transmembrane region, and a C-terminal cytoplasmic tail. LDLR is primarily expressed in the liver but is also found in the adrenal cortex.2 It mediates the endocytosis of LDL by binding to apolipoprotein E (ApoE) or ApoB on the LDL surface, thereby supplying cholesterol to cells.1 Protein levels of LDLR are decreased in HepG2 cells expressing proprotein convertase subtilisin kexin 9 (PCSK9).3 Knockout of Ldlr increases plasma levels of cholesterol and triglycerides and induces the formation of atherosclerotic lesions in mice.4 Mutations in LDLR are associated with familial hypercholesterolemia.5 Cayman’s LDL Receptor Rabbit Monoclonal Antibody (PE) (Clone 032) is composed of an LDLR monoclonal antibody conjugated to phycoerythrin (PE) and can be used for flow cytometry (FC).WARNING This product is not for human or veterinary use.
